Comments

Compugen Stock Price, Quotes and Forecasts

CGENNASDAQ
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$1.39
0.000.00%
At close: -
$1.34
-0.05-3.60%
After Hours: 9:28 AM EDT
Q1 2025 earnings were released today before the market open
Today's conference call ended over 14 hours ago Click to view the webcast

Compugen (CGEN) Forecast

NewsEarningsCompugen (CGEN) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings

Compugen Stock Price, Quotes and Forecasts | NASDAQ:CGEN | Benzinga

Explore Compugen stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CGEN.

Open$1.34
Close$1.39
Volume / Avg.267.32K / 283.06K
Day Range$1.30 - $1.41
52 Wk Range1.13 - 2.66
Market Cap$125.31M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
49
Short Interest
1.9%
Days to Cover9.99

Recent News

Alterity Up on Interim Data From Advance MSA Study
Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease.
Zacks
Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data
Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, an investigational gene therapy for treating Friedreich ataxia (FA) cardiomyopathy.
Zacks
UniQure Soars on New Huntington's Disease Study Data
uniQure N.V. (NASDAQ: QURE) surged 76.5% on Jul 9 after it announced updated interim data, including up to 24 months of follow-up data, from 29 treated patients enrolled in the ongoing early to mid-stage studies of AMT-130 for Huntington's disease in the United States and EU.
Zacks

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Rating and Forecast
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
Open$1.34
Close$1.39
Volume / Avg.267.32K / 283.06K
Day Range$1.30 - $1.41
52 Wk Range1.13 - 2.66
Market Cap$125.31M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
49
Short Interest
1.9%
Days to Cover9.99
About
Sector
Healthcare
Industry
N/A
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
CGEN

FAQ

Q

How do I buy Compugen (CGEN) stock?

A

You can purchase shares of Compugen (NASDAQ:CGEN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Compugen (CGEN) competitors?

A

There are no as such competitors for Compugen.

Q

What is the forecast, or price target, for Compugen (CGEN) stock?

A

Compugen has a consensus price target of $5.42.

Q

What is the current price for Compugen (CGEN)?

A

The stock price for Compugen (NASDAQ: CGEN) is $1.34 last updated May 19, 2025 at 9:28 AM EDT.

Q

Does Compugen (CGEN) pay a dividend?

A

There are no upcoming dividends for Compugen.

Q

When is Compugen (NASDAQ:CGEN) reporting earnings?

A

Compugen’s Q2 earnings are confirmed for Tuesday, August 5, 2025.

Q

Is Compugen (CGEN) going to split?

A

There is no upcoming split for Compugen.

Q

What sector and industry does Compugen (CGEN) operate in?

A

Compugen is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved